Targeting a key driver of Non-Hodgkin Lymphoma using artificial intelligence
Official title: Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI
Funded at Baylor College of Medicine · NIH-10985003 · Data updated 2026-11-12
This study is using smart computer technology to find new ways to create medicines that can help people with Non-Hodgkin Lymphoma by targeting specific proteins that are hard to treat, especially those linked to a common gene mutation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | December 16, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $656,085 |
| NIH project number | 5R01CA271546-03 |
| Project ID | NIH-10985003 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Non-Hodgkin Lymphoma, particularly those with mutations in the MYD88 gene.
✕Less likely to help
Patients with other types of cancers not related to Non-Hodgkin Lymphoma or those without MYD88 mutations may not benefit from this research.
What this research studies
This research focuses on using artificial intelligence to discover and optimize inhibitors for specific proteins that drive Non-Hodgkin Lymphoma (NHL). The collaboration between Baylor College of Medicine and Atomwise aims to tackle the challenge of targeting 'undruggable' oncoproteins, particularly those associated with mutations in the MYD88 gene, which is commonly altered in various types of NHL. By leveraging AI technology, the project seeks to enhance the development of new therapeutic options for patients suffering from this cancer. The approach involves analyzing genetic mutations and their effects on immune response to create targeted treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with Non-Hodgkin Lymphoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using AI to identify drug targets in cancer, indicating that this approach could yield significant advancements in treatment.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Li, Yong — Baylor College of Medicine
- Study coordinator: Li, Yong
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.